NP and PA

Speaking about device-based acne treatments at Maui Derm for Dermatologists 2020 meeting, Fernanda Sakamoto, Ph.D., M.D., discussed PDT and other approaches for targeting the sebaceous gland.

Hilary E. Baldwin, M.D. discusses advances in acne treatment that have expanded treatment options, allowing physicians to improve outcomes in patients with moderate-to-severe acne.

Eli Lilly announces the U.S. Food and Drug Administration approval of ixekizumab (Taltz) for treatment of moderate-to-severe plaque psoriasis in pediatric patients 6 and under 18 who are also eligible for phototherapy and systemic therapy.

HEINE, a global primary diagnostic instrument manufacturer, announces two new dermatoscopes available for purchase in the U.S.

Read more on the variety of new treatment options for acne, with even more awaiting approval.

Read insights from James Q. Del Rosso, D.O., as he discusses antibiotic resistance, isotretinoin relapse, and laboratory monitoring for patients on isotretinoin and spironolactone.

It is important for clinicians to stay abreast with the latest data coming out of trials and individually consult their hair loss patients accordingly on a case by case basis, says this expert.

James J. Leyden, M.D., has four decades of experience prescribing isotretinoin for the treatment of severe acne both in clinical practice and clinical research. Read his conclusions about dosing and use of the oral retinoid in this article.

Rhinophyma is a disfiguring condition with deleterious psychosocial and functional consequences, and its pathogenesis remains unclear. Deborah S. Sarnoff, M.D., offers insight on its etiology, and treatment options in this article.

Although the fractional ablative CO2 laser is a first-line treatment for acne scarring, the potential for side effects from repetitive treatments leaves room for improvement with additive therapies, according to a recent review.

A study showing differences in baseline characteristics between responders to anti-tumor necrosis factor (anti-TNF) therapy and insufficient responders may be helpful to dermatologists as they consider treatment for patients with moderate-to-severe psoriasis, according to the investigators.

Switching patients with moderate-to-severe plaque psoriasis from one biologic to another is a multifactorial decision and may depend on safety, efficacy or dosing intervals. Ron Vender, M.D., offers insight into how to switch appropriately.

Topical ivermectin cream, 1% (Soolantra, Galderma) represents an advance in treatment for rosacea, offering superior efficacy and tolerability compared with previously available therapies, says Jeffrey S. Fromowitz, M.D., who spoke at the Orlando Dermatology Aesthetic & Clinical Conference.

Positive phase 3 results from two clinical trials suggests that Sol-Gel’s novel 5% microencapsulated benzoyl peroxide cream may offer quick, effective relief for patients with papulopustular rosacea.

Sun Pharma introduces a lower dose isotretinoin capsule in the U.S. for the treatment of severe recalcitrant nodular acne.

The atopic dermatitis treatment dupilumab could offer a therapeutic option for keloids, according to a case report published in the Journal of European Academy of Dermatology and Venereology.

Anneke Andriessen, Ph.D. discusses research that suggests controlling symptoms with moisturizers can be an important - and inexpensive - prevention and treatment tactic for pediatric patients with atopic dermatitis.

A novel cocktail of topically applied botanicals has recently proven useful in the treatment and management of mild-to-moderate atopic dermatitis in children, offering hope for this patient population.

Newer treatment approaches may soon become mainstream in the treatment and management of keloids, one expert says.

George Martin, M.D., presented diagnostic and treatment tips on actinic keratosis, basal cell carcinoma and squamous cell carcinoma at the Maui Derm NP + PA summer 2019 meeting.

Kevin S. Pinski, M.D., shared what providers need to know and do to prevent and manage injectable complications at the Maui Derm NP + PA summer 2019 meeting.

A recent preclinical trial reveals that oxymetazoline in combination with pulsed dye laser may increase vascular shutdown in patients with rosacea and other cutaneous vascular diseases.

Evidence that points to interleukin-17 playing a role in the development and progression of rosacea also indicates research should investigate IL-17 inhibition as a therapeutic option for some patients, an expert says.

Suneel Chilukuri, M.D. presented on the science of neuromodulators at the October Maui Derm NP + PA Fall 2019 meeting in Asheville, N.C. Read insights gleaned from his presentation in this article.

Matthew J. Zirwas, M.D., presented a comprehensive primer on the drug types at the October Maui Derm NP + PA Fall 2019 meeting in Asheville, N.C. Read his insights in this article.